Tony's Diary Package — page 1026
of 1141 pages
← p.1025 p.1027 → · this page in the original PDF · package
Was a
yn Network to test COVID vaccines and treatments.
JatientMay 24:
NIH created a public COVID-19 OpenData Portal to openly and quickly share COVID-19-related
drug repurposing data and COVID-19 variant-specific effects against all approved drugs. It was a
key resource for the ACTIV Tracking Resistance And Coronavirus Evolution (TRACE) efforts.
Blurb: COVID-19 OpenData Portal shares data on drug repurposing and variant effects with
drugs.
Image: 5.20 COVID Data Portal variants
July 8:
NIH launched the COVID-19 Prevention Network (COVPN), a clinical trials network to test
COVID-19 vaccines and other prevention tools.
Press release
Blurb: NIH launched COVID-19 Prevention Network to test COVID vaccines and treatments.
July 27:
The Phase 3 clinical trial started for the investigational vaccine mRNA-1273, co-developed by
NIH and Moderna. The trial enrolled approximately 30,000 adult volunteers who did not have
COVID-19.
Press release
Blurb: NIH/Moderna COVID vaccine Phase 3 clinical trial began, enrolling ≈30,000 adult
volunteers.
Image: https://www.shutterstock.com/image-photo/covid19-vaccination-asian-male-patientgetting-1831245058
August 4:
NIH launches the first ACTIV clinical trials to test the safety and efficacy of treatments both for
mild and moderate COVID-19 patients and for patients hospitalized with COVID-19.
ACTIV-2 press release, ACTIV-3 Press Release
Blurb: First ACTIV trials to evaluate the safety and efficacy of COVID therapeutics begin.
Image: 8.4.20 ACTIV trials
September 16:
Recognizing the need to ensure inclusive participation in vaccine trials, NIH launched
Community Engagement Alliance (CEAL) Against COVID-19 Disparities. CEAL provided outreach
and engagement opportunities in racial and ethnic minority communities disproportionately
affected by the COVID-19 pandemic. (In 2021, NIH supplemented the effort with $29 million in
funding from the American Rescue Plan).
September press release
Blurb: NIH launched CEAL to ensure diversity in vaccine trials and reach out to
disproportionately affected communities.
Image: 9.16.20 CEAL
This is our OCR of the page, with running headers and footers removed. The
Committee's PDF
is authoritative; quote from it. Machine-readable, including the uncleaned
text: /api/page/fauci_diary/1026
Records on this page
| Record | Date | Type | Pages |
|---|---|---|---|
| August 16, 2022 | 2022-08-16 | diary entry | 1023–1031 |